相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCICCTG intergroup trial MA.17
Hyman B. Muss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors
Jennifer A. Ligibel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer
Katherine D. Crew et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
L. Mauriac et al.
ANNALS OF ONCOLOGY (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study
Rowan T. Chlebowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A pooled analysis of bone marrow micrometastasis in breast cancer
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial
F Boccardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Physical activity and survival after breast cancer diagnosis
MD Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction
J Melnikow et al.
CANCER (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer:: Results at 4 years
MJ Slade et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years
HJ Stewart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
分享论文
